<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04194541</url>
  </required_header>
  <id_info>
    <org_study_id>20191046</org_study_id>
    <nct_id>NCT04194541</nct_id>
  </id_info>
  <brief_title>Wound Dressings for Hidradenitis Suppurativa</brief_title>
  <official_title>Wound Dressings for Hidradenitis Suppurativa</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Miami</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Miami</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary purpose of this research is to determine how the types of wound dressings affect
      quality of life for people with Hidradenitis Suppurativa (HS).
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 28, 2020</start_date>
  <completion_date type="Anticipated">June 1, 2021</completion_date>
  <primary_completion_date type="Anticipated">January 1, 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in Quality of Life (QoL) as measured by Dermatology Life Quality Index (DLQI)</measure>
    <time_frame>Baseline, 6 Weeks</time_frame>
    <description>DLQI has a total score ranging from 0-30 with the higher score indicating more impairment on the participant's quality of life.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in average pain as assessed by the Numerical Rating Scale (NRS)</measure>
    <time_frame>Baseline, 6 Weeks</time_frame>
    <description>The average pain reported over the last 24 hours will be measured using the NRS with scores ranging from 0-10 with the higher score indicating more severe pain.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in maximal pain as assessed by the Numerical Rating Scale (NRS)</measure>
    <time_frame>Baseline, 6 Weeks</time_frame>
    <description>The pain rating at its worse over the last 24 hours will be reported as the maximal pain using the NRS with scores ranging from 0-10 with the higher score indicating more severe pain.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in sleep rating</measure>
    <time_frame>Baseline, 6 Weeks</time_frame>
    <description>Sleep rating will be evaluated using a 5 point Likert scale ranging from 1-5 with the higher score indicating increased sleep disturbance.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in drainage rating</measure>
    <time_frame>Baseline, 6 Weeks</time_frame>
    <description>Lesion drainage rating will be evaluated using a 4 point Likert scale ranging from 1-4 with the higher score indicating increased lesion draining.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in odor rating</measure>
    <time_frame>Baseline, 6 Weeks</time_frame>
    <description>Lesion odor rating will be evaluated using a 4 point Likert scale ranging from 1-4 with the higher score indicating increased lesion odor.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hidradenitis Suppurativa Physician Global Assessment (HS-PGA) Scores</measure>
    <time_frame>6 Weeks</time_frame>
    <description>HS-PGA Scale scores patient disease severity as one of the following: clear, minimal, mild, moderate, severe, and very severe. The number of participants scored at each scale will be reported at baseline and 6 weeks.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Average frequency of dressing changes</measure>
    <time_frame>6 Weeks</time_frame>
    <description>Participant reported frequency of dressing changes</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall dressing preference</measure>
    <time_frame>6 Weeks</time_frame>
    <description>Overall dressing preference will be reported as the number of participants preferring to use a particular wound dressing in the kit provided.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Dressing preference for body part</measure>
    <time_frame>6 Weeks</time_frame>
    <description>Participant reported dressing preference for specific body parts.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Hidradenitis Suppurativa</condition>
  <arm_group>
    <arm_group_label>Treatment Group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will be provided a kit containing 3 dressings: Cutimed Sorbact Hydroactive B, Cutimed Siltec, and Sorbion Sana multi-star. Participant can use their dressing of choice and can change their dressings as needed for 6 consecutive weeks.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Cutimed Sorbact Hydroactive B wound dressing</intervention_name>
    <description>Wound dressing applied and changed as needed.</description>
    <arm_group_label>Treatment Group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Cutimed Siltect wound dressing</intervention_name>
    <description>Wound dressing applied and changed as needed.</description>
    <arm_group_label>Treatment Group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Sorbion Sana multi-star wound dressing</intervention_name>
    <description>Wound dressing applied and changed as needed.</description>
    <arm_group_label>Treatment Group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Men and women â‰¥18 years of age

          -  Diagnosed with Hidradenitis Suppurativa (all stages of disease) by Dermatologist

          -  Presence of at least one lesion with active drainage

          -  Willing and able to provide informed consent

        Exclusion Criteria:

          -  Subjects younger than 18-years-old.

          -  Prisoners

          -  Pregnant or lactating women

          -  Adults unable to consent
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Hadar Lev-Tov, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Miami</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Maria V Muniz</last_name>
    <phone>305-689-2646</phone>
    <email>mmuniz@med.miami.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Leigh Nattkemper, PhD</last_name>
    <phone>305-588-9734</phone>
    <email>lxn202@med.miami.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>University of Miami</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33136</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Maria V Muniz</last_name>
      <phone>305-689-2646</phone>
      <email>mmuniz@med.miami.edu</email>
    </contact>
    <contact_backup>
      <last_name>Leigh Nattkemper, PhD</last_name>
      <phone>305-588-9734</phone>
      <email>lxn202@med.miami.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Hadar Lev-Tov, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>February 2020</verification_date>
  <study_first_submitted>December 9, 2019</study_first_submitted>
  <study_first_submitted_qc>December 9, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">December 11, 2019</study_first_posted>
  <last_update_submitted>February 11, 2020</last_update_submitted>
  <last_update_submitted_qc>February 11, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">February 13, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Miami</investigator_affiliation>
    <investigator_full_name>Hadar Lev-Tov</investigator_full_name>
    <investigator_title>Assistant Professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hidradenitis Suppurativa</mesh_term>
    <mesh_term>Hidradenitis</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

